dimanche 15 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· May 11, 2026

Is Procter & Gamble (PG) Offering A Reasonable Entry Point After Recent Share Price Weakness?

View original at finance.yahoo.com
Is Procter & Gamble (PG) Offering A Reasonable Entry Point After Recent Share Price Weakness? Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 49 additional high-quality undervalued stocks are identified by Simply Wall St beyond Procter & Gamble

    60% confidence
  • Simply Wall St assigns Procter & Gamble a 4/6 valuation score

    60% confidence
  • Recent market attention on PG has centered on its household products staple status and how consumer companies are assessed amid changing spending patterns

    60% confidence
  • Two-stage DCF model estimates PG intrinsic value at $185.60 per share, implying the stock trades at a 21.1% discount

    60% confidence
  • Analysts and internal estimates project PG free cash flow of $14.76 billion in 2026, rising to $21.13 billion in 2035, with analyst inputs through 2028 and Simply Wall St extrapolations thereafter

    60% confidence
  • On a DCF methodology, Procter & Gamble screens as underpriced / undervalued

    60% confidence

Data points we hold from this source

Procter & Gamble · cash14.76 USD
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,959
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,959 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Is Procter & Gamble (PG) Offering A Reasonable Entry Point After Recent Share Price Weakness?: Source | Via News | fr.via.news